FIND YOUR IDEAL PHARMA/BIOTECH FACILITY
Browse our available pharmaceutical and biotech manufacturing facilities
to find the perfect fit for your unique needs.
Browse our available pharmaceutical and biotech manufacturing facilities
to find the perfect fit for your unique needs.
Midwest U.S.
60,000 SF
60,000 SF small molecule API facility with pilot scale and commercial scale capabilities for sale in the Midwest U.S. Contact Sean McKee at smckee@pharmabiosource.com for more information.
Marketing FlyerPlease find below a sampling of Biotechnology, Life Sciences, and Pharmaceutical Facilities we either represent or have knowledge of. If any particular facility is of interest to you or maybe you have more specific needs, please don’t hesitate to contact us at info@pharmabiosource.com or phone us at 610.293.0900.
Charleston, SC
270,000 SF
PharmaBioSource Realty represented SHL Medical (www.shl-medical.com) on the lease of its new U.S. medical device injection molding manufacturing facility in Charleston, SC. The facility totals 270,000 SF of space and SHL is planning a $90M investment. Once operational in 2024, SHL will employ 165 staff to support its growing autoinjector device manufacturing demands. LEASED
Read Press ReleaseBuena, NJ
110,000 SF
PharmaBioSource Realty is exclusively marketing an operating topical liquids and creams, and injectable fill / finish manufacturing facility located in the U.S. The facility houses 4 compounding suites, a dedicated XP-rated solvent suite and 3 packaging lines for topical liquids, creams, ointments, gels and suspensions. The facility also houses a brand-new injectable fill / finish area with a Bausch VarioSys vial / ampoule filling line. Interested parties should contact Sean McKee at smckee@pharmabiosource.com for a confidential discussion. SOLD
Marketing FlyerSellersville, PA
221,239 SF
PharmaBioSource Realty exclusively represented G&W Laboratories to divest its oral solids, liquids, creams and ointments manufacturing and packaging operation. Piramal Pharma Solutions acquired the fully staffed site which also included a supply agreement.
Press ReleaseRiviera Beach, Florida
73,550 SF
PharmaBioSource Realty exclusively represented the sale of Micelle BioPharma’s soft gel development, manufacturing and laboratory assets and the lease of its 73,550 SF facility.
Read Press ReleaseMilford, MA
93,000 SF
PharmaBioSource Realty exclusively represented Shire to sell its Milford, MA roller bottle manufacturing facility to Rentschler Biopharma.
Press ReleaseKrems, Austria
340,000 SF
Shire’s utility-ready biologics / vaccines manufacturing site acquired by Merck Animal Health.
Press ReleaseHayward, CA
Shire’s mammalian cell culture manufacturing facility with 3 x 2,000L single-use bioreactors acquired by Lonza Biologics.
Malvern, PA
Teva’s 40,000 SF small molecule API research and development facility with kilo labs and pilot plant leased to Flamma.
Brooklyn Park, MN
Baxalta’s mammalian cell culture biologics API manufacturing facility with 2 X 10,000L bioreactors sold to Takeda.
Commack, NY
Actavis (former Forest Labs) 103,530 SF solid dosage development and manufacturing facility located on Long Island, NY sold to Ropack Pharma Solutions.
Hauppage, NY
Actavis (former Forest Labs) 110,186 SF clinical packaging and warehouse facility located on Long Island, NY sold to Ropack Pharma Solutions.
Andover, MA
Eisai’s 60,000 SF high potency small molecule API development and manufacturing facility sold to Sarepta Therapeutics.
Corona, CA
Actavis (former Watson Pharmaceuticals) 285,433 SF solid dosage packaging facility acquired by Bristol Youcare.
Corona, CA
Actavis (former Watson Pharmaceuticals) 196,613 SF solid dosage manufacturing facility acquired by Bristol Youcare.
Pearl River, NY
Leased 78,000 SF of Pfizer’s biologics manufacturing facility to Protein Sciences.
West Lebanon, NH
Olympus Biotech’s 180,000 SF mammaliam cell culture manufacturing facility sold to Novo Nordisk.
Bristol, TN
Sold Pfizer’s 400,000 SF oral and semi-solid dosage form manufacturing facility for tablets, capsules and creams / ointments with controlled substances capabilities to UPM Pharmaceuticals.
Caguas, Puerto Rico
475,000 SF Pfizer oral dosage manufacturing operation with high containment and controlled substances capabilities, contracts and staff sold to Neolpharma.
Brooklyn Park, MN
Genmab’s 215,000 SF facility with 22,000L of mammalian cell culture capacity sold to Baxter Biosciences.
Rochester, MI
King Pharmaceuticals parenteral manufacturing business with 12 branded generic hospital products sold to JHP Pharmaceuticals.
Horsham, PA
Sold the Neose 50,000 SF GMP pilot plant with preclinical, Phase I and Phase II capability to 2,000L.
Morpeth, UK
Pfizer’s 500,000 SF multi-product, multi-use development and manufacturing campus with staff and contracts sold to Nicholas Piramal.
Dorado, Puerto Rico
Sold Biovail’s 175,000 SF solid dosage manufacturing operation to Blu Pharmaceuticals.
Lakewood, NJ
Subleased 221,000 SF of DPT Labs liquids and creams manufacturing facility to Accupac.
Carolina, Puerto Rico
Sold AstraZeneca’s 80,000 SF solid dosage manufacturing facility in Carolina, Puerto Rico.
Miami, FL
Teva’s 90,000 SF sterile manufacturing facility with associated lab and warehouse acquired by Becton Dickinson.
Piscataway, NJ
Subleased 30,000 SF of Enzon’s biologics pilot plant and process development laboratories to Axcellerate Pharma.
Cambridge, MA
Leased 40,000 SF of Draper Labs biotech laboratories to Percivia, a joint venture between DSM and Crucell.
Gaithersburg, MD
Leased Intercell’s 54,000 SF microbial fermentation and patch manufacturing facility.
Devon, PA
Nycomed’s 155,200 SF research lab facility with multi-function pilot plant sold to Merck Research Labs.
